Testimony of Loren Adler, MS
Associate Director and Fellow, USC-Brookings Schaeffer Initiative for Health Policy
Economic Studies, Brookings Institution

Before the United States House of Representatives
Committee on Energy and Commerce
Subcommittee on Health

Lowering Unaffordable Costs:
Legislative Solutions to Increase Transparency and Competition in Health Care

April 26, 2023
Chairman Guthrie, Ranking Member Eshoo, members of the Subcommittee, thank you for the opportunity to testify today on this crucial topic. My name is Loren Adler and I am a Fellow and Associate Director of the USC-Brookings Schaeffer Initiative for Health Policy. My research focuses on health care market competition, provider payments, and prescription drug policy. Prior to joining Brookings, I worked for the Committee for a Responsible Federal Budget and the Bipartisan Policy Center.

Relevant to today’s hearing, much of my current research aims to decipher the effects of private equity, payer, and hospital acquisitions of physician practices, as well as develop policy responses.

I have previously written on a broad array of policy options to reduce costs by increasing transparency and competition in health care – most recently in a policy brief with Benedic Ippolito at the American Enterprise Institute.¹ This testimony focuses more narrowly on two main points:

1) Medicare rates are intended to reflect the costs of providing services for an efficient provider. As such, Medicare should not pay more for the same service performed in a hospital outpatient department versus a physician’s office, provided that the physician’s office setting is safe and clinically effective for most patients. Implementing this policy change would result in substantial savings for beneficiaries and taxpayers, while fostering greater competition in physician markets by reducing incentives for hospitals to acquire physician practices.

2) Increased transparency can both facilitate stronger research and oversight and, in certain circumstances, steer patient volume to lower-cost providers. Specifically, with systematic data about provider ownership arrangements and commercial market prices and volumes, researchers could better identify the effects of various forms of health care consolidation and elucidate solutions. The opacity of payment flows between specific actors in the drug supply chain similarly inhibits research. And evidence suggests that patients can make use of transparent pricing information for more “shoppable” services.

Background

In 2021, the U.S. devoted 18.3% of its economy to pay for health care, a higher share than any other country.² These high costs stem not only by a higher willingness to pay for care, but also insufficient competition in many markets and other market inefficiencies. Elevated health care costs have far-reaching consequences, straining government budgets, hindering wage growth, and affecting individual finances.³

The health care industry has in recent years experienced significant consolidation, both horizontal and vertical. Horizontal consolidation, such as the merging of hospitals or physician groups within the same


The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.
The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.

geographic market, leads to higher prices for consumers and potentially diminished quality of care. With greater market power as an employer locally, there is also evidence that hospital mergers reduce the wages paid to hospital staff with industry-specific skills such as nurses.

Private equity firms have also driven substantial horizontal consolidation in many physician specialty markets (Exhibit 1), often focused in specialties that have seen fewer hospital acquisitions. As expected, empirical evidence suggests that these acquisitions have substantially increased health care costs.

\[\text{Exhibit 1. National private equity penetration in 2019, by specialty}\]

Source: Singh et al. (JAMA Health Forum, 2022). Adler, Milhaupt, and Valdez (Health Affairs Scholar, forthcoming).


5 Arnold and Whaley, 2020


“Vertical” consolidation involving hospitals and physician groups (Exhibit 2) also appears to drive up costs, but the impact on the quality of care remains unclear. These effects likely operate through multiple channels. Hospital-physician integration directly increases Medicare spending because the program pays substantially more money for the same service when performed in a hospital outpatient department rather than an independent physician’s office. Bringing together multiple physician practices in the same specialty under a hospital can effectively bring about horizontal consolidation, increasing the joint entity’s bargaining power. There is also strong evidence that hospital-owned physician practices are more likely to refer patients to their own hospitals and away from lower intensity sites of care, effectively strengthening the hospital’s bargaining power vis a vis insurers.


The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.
Despite evidence pointing to potential antitrust concerns, glaringly so in the case of horizontal consolidation, many acquisitions proceed unchallenged due to factors including insufficient pre-merger notification requirements, data limitations, and resource constraints faced by federal antitrust agencies.

**Site-Neutral Payments**

Many health care services can be delivered either through a physician’s office, an ambulatory surgery center (ASC), or a hospital outpatient department (HOPD). For some services, such as medical emergencies or complex surgeries, there may be safety and quality benefits to receiving care at a HOPD, where there exists emergency standby capacity and other specialists in the case of complications. But for lower-complexity services such as office visits, imaging, and drug administration, it is typically safe and clinically effective to receive care at a physician’s office.  

Yet Medicare pays substantially more – typically between two and three times more – even for low complexity services when delivered in a HOPD rather than a physician’s office. Similarly, Medicare pays more for the same service in a HOPD compared to an ASC, and (to a lesser extent) in an ASC versus a physician’s office. For instance, in their June 2022 report, the Medicare Payment Advisory Commission (MedPAC) notes that “Medicare pays 141 percent more in an HOPD than in a freestanding office for the first hour of chemotherapy infusion … [and] 105 percent more in on-campus HOPDs than in freestanding offices for a midlevel office visit.”

When Medicare pays more, Medicare beneficiaries also pay more, both because they are generally responsible for coinsurance equal to 20% of the Medicare rate and because Medicare Part B premiums and deductibles are tied to a percentage of program costs.

Using the example presented by MedPAC in their March 2023 meeting, a Medicare patient receiving a Level 2 nerve injection at a physician’s office in 2023 would owe $51 in coinsurance on the total Medicare rate of $256. If that same patient instead received the same service at a HOPD, they would owe nearly three times as much – $148 in coinsurance on a total Medicare payment of $741.

This market distortion created by Medicare policy also incentivizes hospital acquisitions of physician practices. This financial incentive can be quite large. For an independent physician in 2016, integrating with a hospital would have increased total annual Medicare payments for their services by $141,000, on average (or nearly $180,000 in today’s dollars). While not the only factor driving vertical consolidation

---


13 Ibid.

14 For beneficiaries with supplemental coverage who are shielded at least in part from the higher coinsurance, those additional costs translate to higher Medigap premiums, costs to their employer, or higher state Medicaid program costs.


The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.
between hospitals and physicians, evidence suggests that Medicare’s policy of paying more for the same service when performed in a HOPD has played a substantial role.\(^\text{17}\)

As discussed earlier, vertical consolidation then also has the knock-on effect of increasing health care costs for employers and individuals in the commercial market.

Medicare has taken small steps toward site-neutral payments, first with the Bipartisan Budget Act of 2015 (BBA). That law reduced Medicare payments to off-campus HOPDs to align with physician fee schedule rates, but excepted (or grandfathered) any off-campus HOPD established before November 2, 2015 (the exception was subsequently expanded to protect any off-campus HOPD under construction by that time). The Trump Administration, through rulemaking, then expanded site-neutral payments to office visits at grandfathered off-campus HOPDs.\(^\text{18}\)

The justification for paying more for the same service delivered at an off-campus HOPD is particularly weak. Often a hospital would acquire a physician practice and rebrand it as a HOPD with little to no noticeable difference to patients. For example, Dranove and Ody (2019) note how an acquired physician group assured its patients that “our diagnostic testing services will still be provided at the same office locations but will be billed as outpatient hospital procedures. Our staff members caring for you in these areas and the services rendered will remain the same.”

But less than 1% of hospital outpatient spending occurs at HOPDs subject to the BBA 2015 changes, and “only one-third of the office visits provided in HOPDs occur in off-campus [HOPDs].”\(^\text{19}\) There are also relatively few limits on expanding grandfathered off-campus HOPDs.

Therefore, while modest improvements have been made, Medicare payment policy continues to encourage vertical consolidation by offering higher payments for the same service when performed at grandfathered off-campus HOPDs (other than office visits), on-campus HOPDs, ASCs, freestanding emergency departments, and cancer hospitals, compared to at a physician’s office.

MedPAC has recommended and this Subcommittee is considering legislation that would end the exception for off-campus HOPDs established before 2015 for all services and align payments between on-campus HOPDs and independent physician offices for a set of low complexity services. These proposals would also align payments between ASCs and HOPDs for certain services that can be safely delivered in an ASC.\(^\text{20}\) Office visits, imaging, and drug administration comprise two-thirds of the services, by program spending, that MedPAC identifies where it is safe and clinically effective to deliver care at a physician’s office (Exhibit 3).

---


\(^{19}\) MedPAC June 2022

\(^{20}\) Ibid.

The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.
Taken together, the Congressional Budget Office (CBO) estimated that a similar combination of policies proposed by the Trump Administration would reduce Medicare spending by $140 billion over 10 years.\(^{21}\) And MedPAC estimated that their June 2022 proposal would have reduced aggregate beneficiary cost-sharing by $1.7 billion in just the year 2019 had it been in place.\(^{22}\)

Some hospital groups have argued that their payment rates should be higher for the same service because they treat sicker patients. While it is true that HOPD patients tend to have higher risk scores than those treated in physician offices, on average, the policy changes under consideration are focused on low complexity services where the cost of providing care does not appear to differ by patient health status. Hospital outpatient departments can also still bill for additional services for patients requiring more intensive care.\(^{23}\)

Moving toward site-neutral payments for services that can be safely delivered in a physician’s office offers an opportunity to substantially reduce costs for taxpayers and beneficiaries while removing one of the most glaring incentives for consolidation. Similar policies have been proposed in both Obama and

---


\(^{22}\) MedPAC June2022

\(^{23}\) Zabinski, MedPAC, 2023

The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.
Trump budgets,\textsuperscript{24} and generate widespread bipartisan support from think tanks and other policy experts.\textsuperscript{25}

Transparency

Many of the proposals under consideration by the Subcommittee today would enhance transparency for researchers, patients, and employers.

The data necessary to best understand health care market dynamics and how new policies will affect the system are often difficult or impossible to access, in many cases controlled by private actors who benefit from opacity. Tracking and analyzing growing trends such as private equity and payer acquisitions of physician practices are hampered by a lack of systematic data on the parent companies and ownership structures of physician group owners.

Two transparency proposals, in particular, would provide better tools for research and oversight:

1) **Requiring entity-level reporting on the parent company name, address, and ownership structure (e.g., private equity, health plan, hospital) of physician practices and making this data publicly-available.** At present, my attempts (and those of collaborators) to compile this sort of information requires a painstaking amount of manual effort on top of purchasing access to privately-held data resources, and is inevitably subject to some level of imprecision given the manual steps involved. Instead, if such information was reported to the government, the Centers for Medicare and Medicaid Services could make available a longitudinal dataset that identifies the parent company and ownership structure of physician groups matched to identifiers for each clinician who treats Medicare patients.

2) **Codifying reporting by insurers under the Transparency in Coverage rules.** The Transparency in Coverage rules require that health insurance plans and issuers make public a treasure trove of data on contracted prices for health care services and amounts paid for out-of-network services. These data offer an opportunity to get a more complete picture of our health care system and examine heterogenous effects across payers. The size and varied reporting structures, however, limit the data’s usability. The proposal under discussion by this Subcommittee would helpfully codify this data reporting, but could be improved to require more standardized reporting (similar to the Subcommittee’s proposal with respect to the hospital transparency data) and reporting on the volume of each service paid for by the health plan.


The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.
For consumers, evidence suggests that meaningful price transparency can place modest downward pressure on health care prices, at least for “shoppable” services such as imaging. The proposed codification and standardization of both the hospital and insurer transparency rules, including the requirement for patient-facing tools that provide real-time information, likely offer the greatest benefits in this respect.

Lastly, there is likely value to increasing transparency into the role of pharmacy benefit managers (PBMs) and payment flows between specific actors throughout the pharmaceutical supply chain. CBO, for instance, estimates that transparency about PBM rebates and other fees can help some plan sponsors negotiate better deals, although such savings are expected to dissipate over time as private actors modify the structure of their contracts. Transparency of drug rebates, payment flows in the drug supply chain, and ownership arrangements can also help foster research to better understand prescription drug markets. For instance, such transparency could make it easier to identify whether vertically-integrated PBMs or pharmacies give worse deals to competing insurers.

Conclusion

The Committee’s focus on bipartisan policies to improve health care competition and transparency is a welcome sight. Thank you again for the opportunity to testify.

---


The views expressed in this testimony reflect those of the author and should not be attributed to the staff, officers, or trustees of the Brookings Institution.